Abstract
Introduction: The aim of the study was to review the long-term survival and outcome of 49 consecutive endoprosthetic lower limb diaphyseal replacements undertaken for neoplastic conditions.
Methods: A retrospective review of all femoral and tibial diaphyseal replacements performed between 1990 and 2009 at our specialist bone and soft tissue tumour unit was performed. Minimum follow-up was one year. Joint sparing prostheses were excluded.
Results: 49 femoral (31) and tibial (18) diaphyseal replacements were implanted into 46 patients (31 male, 15 female). Mean age at surgery was 47 years (range 9–79). Surgery was performed for malignancy in 46 cases (97%), of which 41 (89%) were primary bone and soft tissue sarcomas. The predominant pathologies were osteosarcoma (24%), malignant fibrous histiocytoma (14%) and chondrosarcoma (14%). Mean follow-up was 81 months (range 12–221 months). Survival within the follow-up group was 96% at 1 year, 79% at 5 years, and 69% at 10 years. In surviving patients, using revision, recurrence and amputation as endpoints, prosthesis survival was 91% at 1 year, 58% at 5 years, and 33% at 10 years. In total, 13 prostheses underwent revision surgery and there were 3 amputations following diaphyseal replacement. Of these 16 cases, 75% were for aseptic loosening or prosthetic failure, 13% for tumour recurrence, and 13% for infection.
Discussion: Lower limb diaphyseal endoprosthetic replacements are a useful surgical treatment method for patients with malignant neoplastic diaphyseal bone lesions requiring excision and reconstruction. This is both limb salvage and joint-sparing reconstructive surgery.
Correspondence should be addressed to BOOS at the Royal College of Surgeons, 35–43 Lincoln’s Inn Fields, London WC2A 3PE, England.
